Amir is a trained psychiatrist and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, UK. Amir has over 25 years of drug development experience. He has worked at a number of companies including GlaxoSmithKline, Takeda and AstraZeneca, where he has progressed drugs from preclinical development candidates through to first in human and early phase clinical trials. He has led the design of and successfully delivered proof-of-concept studies in addition to leading teams through the design and execution of phase 3 pivotal studies, filing of INDs/ CTAs and NDAs/ MAAs (marketing authorization applications).  

He has worked across multiple indications in psychiatry, including schizophrenia, depression, bipolar disorder, treatment resistant mental illnesses and substance use disorders where he has led multidisciplinary teams, providing strategic direction and clinical and scientific guidance.  

In his current role as Chief Medical Officer at Cybin, Amir leads a team responsible for program leadership and oversees clinical development strategies and progressing novel compounds from preclinical development to proof of concept and ultimately to approval. 

Amir has published across a wide range of clinical topics and brings translational and clinical scientific insight to our programmes. He is also a key member and recognized leader in the industry, speaking regularly at scientific conferences and discussion panels, participating in and leading cross-industry initiatives in scientific societies.